Imaging agent study for head and neck cancer surgery
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing clinical trials.
This study tests whether two special imaging agents can help doctors see head and neck cancer more clearly during surgery. It may help surgeons remove the cancer more completely while sparing healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have squamous cell carcinoma in the head or neck and are scheduled for surgery to remove it
- Your blood counts, kidney, and liver function are within acceptable limits
- You have not had a heart attack, stroke, or uncontrolled heart failure in the past 6 months
- You have no history of allergic reactions to antibodies or iodine
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
This Phase 2 study tests a targeted medicine (panitumumab-IRDye800) given around the time of surgery for head and neck squamous cell cancer. It aims to improve doctors’ ability to find and remove cancer tissue during planned surgery.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
This Phase 1 study tests a new way to use a scan (PET/CT) with a drug called panitumumab to help spot where head and neck squamous cell cancer has spread. It may help doctors better target treatment by finding metastases earlier or more clearly.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.